Tofogliflozin

Tofogliflozin (brand names: Apleway, Deberza) is an SGLT2 inhibitor mainly used in Japan to treat Type 2 Diabetes Mellitus (T2DM), lowering blood sugar by increasing glucose excretion in urine, and also helps with weight loss, blood pressure, and lipids. Beyond diabetes, it shows potential benefits for obesity-related issues like atherosclerosis markers, improving cardiovascular risk factors, and possibly improving heart function, with ongoing research exploring broader applications like preventing certain cancers, though its primary role remains glycemic control. It is grouped under the following drug class(es): Hypoglycemics and SGLT2 inhibitors. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include tofogliflozinum, apleway and deberza. Its PubChem CID is 46908929.

CAS No 903565-83-3
Molecular Formula C22H26O6
Molecular Weight 386.4 g/mol
Synonyms (3S,3'R,4'S,5'S,6'R)-5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol

Frequently Asked Questions